Bispecific antibodies pair CD47 blockade with tumor-restricted antigens (e.g., CD20, EpCAM) to improve selectivity, while conditionally active therapeutics are engineered to activate preferentially within the tumor microenvironment, thereby widening the therapeutic index and minimizing systemic exposure [10]. The gene discussed is CD47; the disease is neoplasm.